win some... schreef op 25 december 2024 12:32:
[...]
Deze informatie is denk ik niet geupdatet. Uit het laatste interimreport van Abliva van 29 november 2024:
Last Wave 1 Patient Completes 48-Week DosingThis month, the program reached a significant milestone with the completion of the 48-week dosing in the final
patient in Wave 1, marking the end of the first phase of the study. When the trial began, we had only administered doses for 10 days; now, we have demonstrated that KL1333 maintains a strong safety profile even after long-term dosing, with no drug-related serious adverse events (SAEs) reported to date.
We are now continuing preparatory activities for the second and final wave of the study, starting subject to financing. The team has been actively preparing for the study’s expansion, including coordinating the documentation needed to support around forty sites across ten countries. Enthusiasm for the study with sites remains high, and we look forward to commencing Wave 2 as soon as possible.